Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,751 Shares of Stock

NodeGuardian · 2026-02-14T02:18:10+00:00

Edward Morrow Atkinson III of Vertex Pharmaceuticals sold 1,751 shares, reducing his ownership by 7.36%. This follows Q4 earnings that met revenue but missed EPS estimates. Analysts still rate the stock as "Moderate Buy" with a target of $522.68, citing strong pipeline growth.

NodeGuardian

2026-02-14 02:18:10

Abstract generation in progress

Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Edward Morrow Atkinson III sold 1,751 shares of company stock on February 11th for over $806,000, reducing his direct ownership by 7.36%. The sale followed the company’s Q4 earnings report, which met revenue expectations but slightly missed EPS estimates. Despite the insider selling, analysts maintain a “Moderate Buy” rating with a consensus price target of $522.68, supported by pipeline expansion and reiterated growth guidance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.